PSMA therapy for prostate cancer that has come back
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a targeted radiation therapy (PSMA-RLT) for men whose prostate cancer has returned after initial treatment, shown only by rising PSA levels. It aims to control the cancer without using hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery and/or radiation for prostate cancer, and your PSA is rising again.
- Your PSA doubling time is 12 months or less.
- You haven't had hormone therapy in the last year, or your testosterone has recovered.
- A PSMA PET scan shows the cancer has not come back in the prostate area, but it may have spread to other parts of the body.
- You are in good overall health (ECOG 0-1) and have adequate blood counts and kidney function.
- You can have no other active cancers or serious medical conditions that limit your life expectancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging scan (POSLUMA) that uses a radioactive tracer to find prostate cancer that has come back or spread after initial treatment. The scan may help doctors plan radiation therapy more accurately for men with recurrent prostate cancer.
This trial looks at using a PSMA PET/CT scan to better re-check cancer activity in men whose PSA has started rising after prostate removal. If you qualify, the scan may help doctors choose the next best treatment step.
This trial tests a radioactive drug (PSMA-RLT) given before surgery for prostate cancer that has spread to a few spots. It aims to see if this treatment can stop the cancer from growing further.
This trial uses a special scan (PSMA-PET) to find where prostate cancer has returned after surgery. Then doctors give a lower dose of radiation only to that area, which may reduce side effects. It is for men whose PSA level is rising after prostate removal.
This trial tests if a second round of a targeted radiation therapy (177Lu-PSMA-617) can help men whose prostate cancer has returned after a successful first treatment. It is for men whose cancer has stopped responding to hormone therapy and chemotherapy, and whose PSA levels have risen again after a prior good response to this drug.
This trial tests whether adding a PSMA-targeted radioactive medicine (Lu-PSMA) to focused stereotactic radiation to a few prostate cancer spots works better than radiation alone. It may help people with limited, asymptomatic spread of prostate cancer by improving cancer control while carefully monitoring side effects.
Hear when a new Prostate Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.